( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Chronic Pain - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets's offering. This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Chronic Pain market. A detailed picture of the Chronic Pain pipeline landscape is provided, which includes the disease overview and Chronic Pain treatment guidelines.
The assessment part of the report embraces in-depth Chronic Pain commercial assessment and clinical assessment of the Chronic Pain pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pain collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details. The report provides insights into: Key Questions Answered Key Topics Covered 1.
Report Introduction 2. Chronic Pain 3. Chronic Pain Current Treatment Patterns 4.
Chronic Pain - Analytical Perspective 5. Therapeutic Assessment 6. Chronic Pain Late Stage Products (Phase-III) 7.
Chronic Pain Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10.
Inactive Products 11. Dormant Products 12. Chronic Pain Discontinued Produ.
